- Conditions
- Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
- Interventions
- BIIB059 (litifilimab)
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 322 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 5:06 AM EDT